MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 890 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Klotho-derived peptide 1 hydrochloride
Klotho-derived peptide 1 (KP1 human) hydrochloride inhibits the interaction between TGF-β and TGF-β receptor 2, suppressing the activation of TGF-β-induced Smad2/3 and mitogen-activated protein kinase (MAPK). Additionally, it exhibits antifibrotic and renal protective effects in mouse models.Cor e Forma:Odour SolidSAH-SOS1A TFA
SAH-SOS1A TFA inhibits SOS1/KRAS interaction, binding wild/mutant KRAS with 106-175 nM affinity and blocks ERK-MAPK signaling, reducing cancer cell viability.Fórmula:C102H160N27F3O30Cor e Forma:SolidPeso molecular:2301.55PPM-3
PPM-3, a selective PROTAC ERK5 degrader, exhibits a potent inhibitory concentration (IC 50) of 62.4 nM.Fórmula:C54H69N11O6SPureza:98%Cor e Forma:SolidPeso molecular:1000.26KRASG12C IN-2
KRASG12C IN-2 (compound 17) is an orally active inhibitor of KRAS G12C, which effectively suppresses tumor growth in mice [1].Cor e Forma:SolidStRIP16
Rab8a GTPase-binding stapled peptide (Kd = 12.7 μM). Cell permeable; localizes to the endomembrane system.Cor e Forma:SolidMEK4 inhibitor-1
CAS:MEK4 inhibitor-1 targets MEK4 enzyme in pancreatic cancer, IC50=61 nM.Fórmula:C13H10FN3O2SCor e Forma:SolidPeso molecular:291.3(+)-Oxanthromicin
CAS:(+)-Oxanthromicin, an enantiomer of the rare Streptomyces metabolite (−)-oxanthromicin, demonstrates inhibitory activity against K-Ras plasma membrane localization in MDCK cells, exhibiting an IC50 value of 62.5 μM.Fórmula:C36H30O12Cor e Forma:SolidPeso molecular:654.624Pan-RAS-IN-6
Pan-RAS-IN-6 (compound 24) serves as a DUSP6 inhibitor, effectively reducing MAPK activation in the NCI-H1373-Luc model (DUSP6). It concurrently exhibits notable tumor growth inhibition and regression in the NSCLC brain metastasis mouse model. The compound displays high selectivity and potent inhibitory effects, particularly on KRAS mutation-associated signaling pathways. It demonstrates varied inhibitory activities against distinct KRAS mutants and their interacting proteins. The IC 50 values for KRAS G12C, G12D, and G12V are 1.3 nM, 4.7 nM, and 0.3 nM, respectively.Fórmula:C46H60N8O5SCor e Forma:SolidPeso molecular:837.08TUS-007
CAS:TUS-007, a non-proteasome inhibiting CANDDY, is an oral KRAS G12D/V degrader for cell-free chemical knockdown and tumor suppression.Fórmula:C44H54Cl2N8O5Cor e Forma:SolidPeso molecular:845.86JIP-1(153-163)
CAS:Peptide based on JIP-1(153-163) inhibits JNK with micromolar affinity; barely affects p38, ERK.Fórmula:C61H104N20O14Pureza:98%Cor e Forma:SolidPeso molecular:1341.6KRAS G12D inhibitor 15
CAS:Potent KRAS G12D inhibitor 15 targets cancer, potential for disease research. (WO2022042630A1, compound 243)Fórmula:C53H71F2N7O5Cor e Forma:SolidPeso molecular:924.17NUCC-0200808
NUCC-0200808 (Compound 12g) is an MNK1 inhibitor with an IC50 of 42 nM. It reduces eIF4E phosphorylation and cell viability in AML cells and induces apoptosis. NUCC-0200808 shows potential for research in the field of leukemia.Cor e Forma:Odour SolidPROTAC MEK1 Degrader-1
CAS:PROTAC MEK1 Degrader-1, a targeted protein degradation agent, combines a MEK1 inhibitor with a von Hippel-Lindau ligand to effectively inhibit ERK1/2Fórmula:C53H66FIN8O11S2Pureza:98%Cor e Forma:SolidPeso molecular:1201.17SOS1-IN-17
SOS1-IN-17 (Compound 8d) is an orally active inhibitor targeting the SOS1-KRASG12C interaction, with an IC50 of 5.1 nM. It suppresses ERK phosphorylation in DLD-1 cells with an IC50 of 18 nM and demonstrates antiproliferative activity in KRASG12C-mutant Mia-Paca-2 cells, with an IC50 of 0.11 μM. In mouse models, SOS1-IN-17 shows antitumor efficacy against pancreatic cancer.Fórmula:C29H34F3N5O2Cor e Forma:SolidPeso molecular:541.61HPK1-IN-4
CAS:HPK1-IN-4 is an HPK1 (MAPK41) inhibitor with an IC 50 of 0.061 nM. HPK1-IN-4 is often used as a preclinical immunotherapy tool compound.Fórmula:C23H26N6O3Pureza:97.06%Cor e Forma:SolidPeso molecular:434.49Ref: TM-T40350
1mg123,00€5mg295,00€10mg447,00€25mg782,00€50mg1.071,00€100mg1.468,00€1mL*10mM (DMSO)326,00€KRAS inhibitor-33
KRAS inhibitor-33 (compound 115a) is a pyrido[2,3-d]pyrimidine derivative that serves as an effective inhibitor of KRAS, exhibiting an IC50 value of ≤ 100nM.Fórmula:C33H39ClF2N6O3Cor e Forma:SolidPeso molecular:641.15BI1701963
BI1701963 is an orally effective inhibitor that targets the SOS1 and KRAS interaction, specifically inhibiting the activation of KRAS by blocking its GTP loading. This compound is utilized in cancer research to explore potential therapeutic effects against KRAS-driven malignancies.Fórmula:C47H62N8O4SCor e Forma:SolidPeso molecular:835.11HPK1-IN-39
HPK1-IN-39 (Compound 10n), a selective inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) with an inhibitory concentration (IC50) of 29 nM, impedes theFórmula:C26H27N7O2Cor e Forma:SolidPeso molecular:469.54YN14
YN14 is a highly potent and selective KRASG12C proteolysis targeting chimera (PROTAC) capable of forming a stable KRASG12C: YN14: VHL ternary complex with lowPureza:98%Cor e Forma:Odour SolidMAP4K4-IN-6
MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor with an IC50 of 80 nM. It reduces the phosphorylation of c-Jun and exhibits neuroprotective effects. Additionally, MAP4K4-IN-6 enhances the vitality of motor neurons and can be utilized in the study of amyotrophic lateral sclerosis (ALS).Cor e Forma:Odour Solid
